See more : Zhejiang Sunoren Solar Technology Co.,Ltd. (603105.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Komplett Bank ASA (0EFW.L) Income Statement Analysis – Financial Results
- WHA Premium Growth Freehold And Leasehold Real Estate Investment Trust (WHART.BK) Income Statement Analysis – Financial Results
- Zug Estates Holding AG (0QPW.L) Income Statement Analysis – Financial Results
- Warner Bros. Discovery, Inc. (DISCK) Income Statement Analysis – Financial Results
- TVS Srichakra Limited (TVSSRICHAK.BO) Income Statement Analysis – Financial Results
Simulations Plus, Inc. (SLP)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.simulations-plus.com
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M | 29.67M | 24.14M | 19.97M | 18.31M | 11.46M | 10.07M | 9.45M | 11.72M | 10.71M | 9.14M | 8.97M | 8.86M | 5.86M | 4.75M | 5.21M | 5.48M | 4.44M | 3.91M | 3.63M | 3.47M | 2.65M | 2.49M | 2.60M |
| Cost of Revenue | 26.86M | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M | 7.99M | 6.31M | 4.60M | 4.32M | 1.63M | 1.65M | 1.51M | 2.88M | 2.55M | 2.32M | 2.10M | 2.08M | 1.60M | 1.51M | 1.56M | 1.54M | 1.46M | 1.56M | 1.16M | 1.65M | 1.76M | 1.25M | 1.20M |
| Gross Profit | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M | 21.67M | 17.83M | 15.37M | 14.00M | 9.83M | 8.42M | 7.94M | 8.84M | 8.17M | 6.82M | 6.87M | 6.78M | 4.25M | 3.24M | 3.65M | 3.95M | 2.99M | 2.35M | 2.47M | 1.82M | 889.25K | 1.24M | 1.40M |
| Gross Profit Ratio | 61.63% | 80.48% | 79.92% | 77.19% | 74.39% | 73.43% | 73.05% | 73.87% | 76.96% | 76.43% | 85.79% | 83.65% | 84.02% | 75.44% | 76.23% | 74.61% | 76.58% | 76.49% | 72.60% | 68.27% | 70.09% | 71.96% | 67.23% | 60.08% | 67.98% | 52.45% | 33.62% | 49.77% | 53.85% |
| Research & Development | 5.75M | 4.50M | 3.21M | 4.05M | 2.97M | 2.50M | 1.79M | 1.37M | 1.45M | 1.33M | 952.77K | 802.37K | 947.56K | 935.20K | 969.87K | 1.11M | 990.49K | 814.95K | 445.25K | 524.56K | 515.02K | 379.63K | 382.14K | 354.09K | 299.88K | 218.51K | 390.45K | 133.02K | 100.00K |
| General & Administrative | 22.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M | 6.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 131.78K | 38.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.27M | 34.72M | 24.97M | 20.57M | 16.36M | 11.80M | 9.58M | 8.20M | 6.69M | 6.81M | 4.44M | 3.55M | 3.38M | 4.31M | 4.33M | 3.90M | 3.70M | 3.46M | 2.97M | 2.42M | 2.51M | 2.30M | 2.11M | 2.20M | 2.14M | 2.31M | 2.68M | 2.28M | 1.20M |
| Other Expenses | 0.00 | 2.97M | 204.00K | 0.00 | 14.30B | 14.30B | 8.14B | 0.00 | 0.00 | 0.00 | 0.00 | 35.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.15K | 0.00 | 0.00 | 0.00 | 100.00K |
| Operating Expenses | 37.02M | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M | 11.37M | 9.57M | 8.14M | 8.14M | 5.39M | 4.35M | 4.33M | 5.24M | 5.30M | 5.01M | 4.69M | 4.27M | 3.42M | 2.95M | 3.02M | 2.68M | 2.49M | 2.55M | 2.70M | 2.53M | 3.07M | 2.41M | 1.40M |
| Cost & Expenses | 63.88M | 50.85M | 39.00M | 35.21M | 29.98M | 23.32M | 19.37M | 15.87M | 12.74M | 12.46M | 7.02M | 6.00M | 5.84M | 8.12M | 7.84M | 7.33M | 6.79M | 6.36M | 5.02M | 4.46M | 4.58M | 4.22M | 3.94M | 4.12M | 3.87M | 4.18M | 4.83M | 3.66M | 2.60M |
| Interest Income | 4.38M | 4.13M | 717.00K | 201.00K | 29.47K | 33.52K | 27.12K | 15.86K | 18.01K | 17.94K | 31.44K | 49.49K | 89.27K | 91.86K | 101.55K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 717.00K | 22.00K | 0.00 | 109.08K | 153.03K | 38.19K | 18.01K | 17.94K | 31.44K | 49.49K | 3.00 | 118.00 | 1.05K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.67M | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M | 2.72M | 2.14M | 1.93M | 1.99M | 1.04M | 766.96K | 715.44K | 747.30K | 682.94K | 561.01K | 543.42K | 512.45K | 363.18K | 206.89K | 223.98K | 195.60K | 191.83K | 293.85K | 261.15K | 503.76K | 632.09K | 139.86K | -100.00K |
| EBITDA | 11.80M | 12.57M | 18.49M | 14.70M | 11.85M | 13.31M | 11.72M | 10.38M | 9.17M | 7.68M | 5.48M | 4.84M | 4.67M | 4.52M | 3.79M | 2.59M | 2.72M | 3.02M | 1.20M | 503.32K | 850.21K | 1.46M | 691.94K | 91.90K | 24.49K | -205.28K | -1.70M | -1.03M | 100.00K |
| EBITDA Ratio | 16.85% | 14.64% | 27.66% | 24.65% | 28.50% | 39.54% | 43.98% | 43.15% | 45.95% | 32.97% | 38.36% | 48.90% | 46.74% | 37.88% | 34.12% | 26.98% | 29.43% | 33.96% | 19.85% | 10.40% | 16.33% | 26.68% | 15.57% | 2.35% | 0.60% | -10.25% | -61.53% | -30.75% | 3.85% |
| Operating Income | 6.13M | 8.73M | 11.34M | 7.86M | 8.89M | 10.65M | 10.30M | 8.26M | 7.23M | 5.86M | 4.44M | 4.07M | 3.61M | 3.60M | 2.87M | 1.81M | 2.18M | 2.50M | 833.14K | 296.43K | 626.23K | 1.27M | 500.11K | -201.95K | -236.66K | -709.05K | -2.18M | -1.17M | 200.00K |
| Operating Income Ratio | 8.76% | 14.64% | 21.03% | 16.92% | 21.38% | 31.35% | 34.71% | 34.24% | 36.21% | 31.98% | 38.74% | 40.44% | 38.23% | 30.72% | 26.80% | 19.82% | 24.29% | 28.26% | 14.23% | 6.24% | 12.03% | 23.07% | 11.25% | -5.16% | -6.52% | -20.45% | -82.58% | -46.90% | 7.69% |
| Total Other Income/Expenses | 6.28M | 2.97M | 204.00K | -168.00K | 2.50M | -92.73K | -158.85K | -24.02K | 4.59K | -163.60K | 73.93K | 184.41K | 342.77K | 169.40K | 233.87K | 214.83K | 268.03K | 121.69K | 55.64K | 51.69K | 72.40K | -7.44K | -13.60K | -22.05K | -19.34K | 133.98K | 116.84K | -305.99K | 0.00 |
| Income Before Tax | 12.41M | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M | 10.14M | 8.24M | 7.24M | 5.69M | 4.51M | 4.26M | 3.95M | 3.77M | 3.10M | 2.03M | 2.45M | 2.62M | 888.78K | 348.12K | 698.63K | 1.26M | 486.52K | -224.00K | -256.00K | -575.07K | -2.07M | -1.48M | 0.00 |
| Income Before Tax Ratio | 17.73% | 19.63% | 28.04% | 23.86% | 27.38% | 31.08% | 34.18% | 34.14% | 36.23% | 31.08% | 39.38% | 42.27% | 41.85% | 32.17% | 28.98% | 22.17% | 27.28% | 29.63% | 15.18% | 7.32% | 13.42% | 22.94% | 10.95% | -5.72% | -7.05% | -16.59% | -78.17% | -59.17% | 0.00% |
| Income Tax Expense | 2.46M | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M | 1.20M | 2.45M | 2.29M | 1.85M | 1.49M | 1.37M | 1.14M | 1.06M | 948.43K | 614.58K | 720.61K | 1.16M | 212.90K | 85.80K | -137.86K | -1.25M | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | -38.80K | 0.00 |
| Net Income | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M | 8.93M | 5.79M | 4.95M | 3.84M | 3.03M | 2.89M | 3.03M | 2.71M | 2.16M | 1.41M | 1.73M | 1.47M | 675.88K | 262.32K | 836.49K | 2.51M | 484.92K | -225.60K | -257.60K | -576.67K | -2.07M | -1.44M | 0.00 |
| Net Income Ratio | 14.22% | 16.72% | 23.16% | 21.05% | 22.44% | 25.27% | 30.12% | 23.98% | 24.79% | 20.98% | 26.40% | 28.66% | 32.05% | 23.16% | 20.13% | 15.44% | 19.24% | 16.55% | 11.54% | 5.52% | 16.07% | 45.69% | 10.91% | -5.76% | -7.10% | -16.63% | -78.23% | -57.62% | 0.00% |
| EPS | 0.50 | 0.50 | 0.62 | 0.49 | 0.52 | 0.49 | 0.52 | 0.34 | 0.29 | 0.23 | 0.19 | 0.18 | 0.19 | 0.17 | 0.14 | 0.09 | 0.11 | 0.10 | 0.05 | 0.02 | 0.06 | 0.18 | 0.04 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| EPS Diluted | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 | 0.08 | 0.10 | 0.08 | 0.04 | 0.02 | 0.05 | 0.17 | 0.03 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| Weighted Avg Shares Out | 19.99M | 20.08M | 20.20M | 20.05M | 17.82M | 17.49M | 17.33M | 17.24M | 17.03M | 16.86M | 16.17M | 16.00M | 15.76M | 15.54M | 15.83M | 16.13M | 16.13M | 15.28M | 14.72M | 14.44M | 13.98M | 13.64M | 13.63M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
| Weighted Avg Shares Out (Dil) | 20.30M | 20.47M | 20.75M | 20.74M | 18.54M | 18.06M | 17.86M | 17.52M | 17.21M | 17.03M | 16.41M | 16.32M | 16.15M | 16.08M | 16.51M | 17.19M | 18.14M | 17.96M | 16.29M | 15.92M | 15.58M | 14.96M | 14.10M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
Can Simulations Plus (SLP) Climb 53.66% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Simulations Plus (SLP) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Simulations Plus (SLP) Q2 Earnings Beat, Revenues Up Y/Y
Simulations Plus' (SLP) Q2 results are driven by higher revenues in Software and Services business segments.
Simulations Plus, Inc. (SLP) Q2 2023 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Earnings Conference Call March 5, 2023 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants François Brisebois...
Simulations Plus (SLP) Surpasses Q2 Earnings Estimates
Simulations Plus (SLP) delivered earnings and revenue surprises of 11.11% and 2.54%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported revenue growth in the 2nd quarter of FY23 with total 2Q revenue up 6% to $15.8 million; YTD revenue up 2% to $27.7 million.
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2023, ended February 28, 2023. Second Quarter Financial...
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
LANCASTER, Calif.--(BUSINESS WIRE)--More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science. Hosted by Simulations Plus, Inc. (Nasdaq: SLP) as...
Simulations Plus (SLP) Joins SACF to Develop Anticancer Drugs
Simulations Plus (SLP) will be working on the development of QSAR models by utilizing information available from both academic/patent literature and SACF to test effectiveness against MTHFD2.
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus collaborates with the Sino-American Cancer Foundation to use its AIDD technology & expertise to discover new anticancer therapies.
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF). This collaboration will...
Source: https://incomestatements.info
Category: Stock Reports